TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Children With Hypophosphatemic Rickets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical, biochemical and genetic diagnosis of XLH~* height SDS \< 2~* at least two years of treatment with oral phosphate and calcitriol~Exclusion Criteria:~* uncontrolled rickets (ALP\>600 IU)~* growth hormone deficiency~* hyperparathyroidism, nephrocalcinosis, renal insufficiency~* associated disease~* previous treatment with growth hormone

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- norditropine simplex (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1-6 months corrected age~* Written parental informed consent~* At least one of the following:~  * Size: hemangioma \>1.5 cm on the face or \>3 cm on other body parts~ * Causing or with potential for functional impairment (e.g. amblyogenic IH, ulcerated hemangioma)~ * Causing or with potential for cosmetic disfigurement (e.g. nasal tip, glabella location)~Exclusion Criteria:~* Contraindications to beta-blockers~  * Hypotension~ * Bradycardia~ * Hypoglycemia~ * Cardiac disease associated with decreased ejection fraction and/or \> second degree heart block~ * Bronchospasm (including bronchial asthma)~ * Allergic rhinitis~* Corrected gestational age less than 1 month at screening~* Patients with PHACES cerebral arteriopathy at risk of stroke~* Patients and/or breastfeeding mothers receiving treatment with anti-arrhythmic agents, calcium channel blockers, ACE inhibitors, inotropic agents, vasodilators, hypoglycemic agents, neuroleptics, antiacids, benzodiazepines, thyroxine, warfarin~* Patients treated with an oral beta-blocker or other agent (e.g. systemic steroids, vincristine) within 2 weeks from randomization~* Patients treated with topical timolol within 1 week from randomization~* Vascular tumors other than infantile hemangioma (e.g. pyogenic granuloma, hemangioendothelioma)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Nadolol group (Type: ACTIVE_COMPARATOR): 40 study participants will take Nadolol (oral liquid suspension)
- Propranolol group (Type: ACTIVE_COMPARATOR): 40 study paticipants will take Propranolol (oral liquid suspension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>35 years~* Exudative, active PCV in 1 eye.~* PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography.~Exclusion Criteria:~* Age \<35 years~* Prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ranibizumab 0.5 mg/ 0.05 cc (Type: EXPERIMENTAL): Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
- Ranibizumab 0.3 mg/ 0.05 cc (Type: EXPERIMENTAL): Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants admitted to Crouse Hospital NICU with MSSA/MRSA colonization that have parental consent for participation obtained within 2 days of their initial positive screen.~Exclusion Criteria:~* Any infant with an active or previous S. aureus infection at time of initial positive S. aureus colonization screen.~* Any infant with a condition thought to be fatal/irreversible (pulmonary hypoplasia, chromosomal/genetic syndromes, fatal cardiac anomalies).~* Any infant with a congenital condition that would prevent specimen collection or treatment application (cleft lip/palate, choanal atresia, abdominal wall defects, imperforate anus, etc.).~* Sufficient length of NICU admission will be necessary to adequately measure the primary outcome. Therefore, enrolled patients will only be included in data analysis if they remain in the NICU until after at least one subsequent MSSA/MRSA screening is performed following completion of their initial treatment course with either mupirocin or placebo.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mupirocin (Type: EXPERIMENTAL): None
- Petroleum jelly (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with penicillin allergy who have non-ulcer functional dyspepsia or scarred peptic ulcer disease~* Ability and willingness to participate in the study and to sign and give informed consent~* confirmed H. pylori infection~Exclusion Criteria:~* Patients without penicillin allergy~* Less than 18 years old~* With previous gastric surgery~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs~* Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tailored Therapy (Type: EXPERIMENTAL): Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged more than 60 years and recipients of compatible renal transplant~Exclusion Criteria:~1. Receptors of multiple organs;~2. non-heart beating donors;~3. donors aged under 5 or over 65 years;~4. Patients with body mass index greater than 35

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus + Mycophenolate (Type: ACTIVE_COMPARATOR): The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %
- Tacrolimus + Sirolimus (Type: EXPERIMENTAL): The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have histologically confirmed squamous cell carcinoma or adenosquamous cell carcinoma of esophagus~* Male or Female at least 18 years of age~* Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out~* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work~* Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study~Exclusion Criteria~* Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment~* Active known or suspected autoimmune disease~* Any serious or uncontrolled medical disorder or active infection~* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)~* Any positive test result for hepatitis B or C indicating acute or chronic infection and/or detectable virus~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): None
- Nivolumab + Cisplatin + Fluorouacil (Type: EXPERIMENTAL): None
- Cisplatin + Fluorouracil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must meet 1987 ACR criteria~2. Age \> 18 years of age~3. Baseline DAS28/ESR\>=3.2~4. Stable concomitant DMARDs~5. Stable prednisone \<10mg or equivalent~6. Power Doppler score of \>=10~7. Female subjects of childbearing potential must test negative for pregnancy~8. Male and female subjects of childbearing potential must agree to use contraception throughout the study~9. Negative QuantiFERON Gold test at screening~Exclusion Criteria:~1. No active TB~2. Prednisone \>10 mg~3. Pregnancy or breast feeding~4. Prior treatment with tofacitinib~5. Concomitant biologic therapy (TNF inhibitors, IL-6 inhibitors, etc.)~6. Active infection with HIV, hepatitis B or C, or herpes zoster~7. Subjects with any uncontrolled clinically significant laboratory abnormality or any of the following laboratory abnormalities:~   1. Evidence of hematopoietic disorder or hemoglobin \<9 g/dL~  2. Absolute lymphocyte count \<0.75 x 109/L (\<750/mm3)~  3. Absolute neutrophil count \<1.2 x 109/L (\<1200/mm3)~  4. Platelet count \<100 x 109/L (\<100,000/mm3)~  5. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (x ULN)~  6. Estimated GFR \<40 ml/min~8. Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)~9. Subjects who require concomitant treatment with medications that are potent inhibitors of cytochrome P450 3A4 (CYP3A4), both moderate inhibitors of CYP3A4 and potent inhibitors of CYP2C19, and potent CYP inducers (See Appendix)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tofacitinib 5mg po bid (Type: OTHER): Open label with tofacitinib 5mg po bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with COPD and FEV1 \<60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio \<70%.~* Current or ex-smokers with a smoking history of at least 10 pack-years.~Exclusion criteria:~* Diagnosis of other respiratory disorders (including asthma).~* Requirement for long term oxygen therapy.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy (CBT) for PTSD in Veterans With Co-Occurring SUDs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least age 18.~* Current SUD diagnosis.~* Score of at least 45 on CAPS.~* Must speak English.~* Must agree to be taped.~Exclusion Criteria:~* Acute psychotic symptoms, if not well connected with appropriate mental health services.~* Severe suicidality.~* Individuals with unstable medical or legal situations that would make completion of the study highly unlikely.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: TAU + CBT (Type: EXPERIMENTAL): The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
- Arm 2: TAU (Type: NO_INTERVENTION): The no intervention group will receive treatment as usual (TAU).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fully understand and voluntarily sign informed consent. 5-15years old. At least one legal guardian and/or Subjects to sign informed consent.~* Clinically diagnosed as β-thalassemia major, phenotypes including β0β0, β+β0,βEβ0 genotype.~* Subjects with no affection with EBV, HIV, CMV, TP, HAV, HBV and HCV.~* Subjects body condition eligible for autologous stem cell transplant.~Exclusion Criteria:~* Subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor.~* Active bacterial, viral, or fungal infection.~* Treated with erythropoietin prior 3 months.~* Immediate family member with any known hematological tumor.~* Subjects with severe psychiatric disorders to be unable to cooperate.~* Recently diagnosed as malaria.~* History of complex autoimmune disease.~* Persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value \>3 X the upper limit of normal (ULN).~* Subjects with severe heart, lung and kidney diseases.~* With serious iron overload, serum ferritin\>5000mg/ml.~* Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or Investigator.~* Subjects who are receiving treatment from another clinical study, or have received another gene therapy.~* Subjects or guardians had resisted the guidance of the attending doctor.~* Subjects whom the investigators do not consider appropriate for participating in this clinical study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- γ-globin reactivated autologous hematopoietic stem cells (Type: EXPERIMENTAL): each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* aged 15\<=~* developed symptoms of orthostatic intolerance accompanied by a HR rise ≥30 min-1 within the first 10 minutes of standing, HR rise ≥ 120 in the absence of orthostatic hypotension (a fall in blood pressure \[BP\] \>20/10 mm Hg).~Exclusion Criteria:~* poor drug compliance~* patients who cannot or do not want to write questionaires.~* patients who do not want draw blood

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: ACTIVE_COMPARATOR): Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
- Bisoprolol (Type: ACTIVE_COMPARATOR): Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
- Propranolol+pyridostigmine (Type: ACTIVE_COMPARATOR): Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
- Bisoprolol+pyridostgmine (Type: ACTIVE_COMPARATOR): start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective anterior approach to subaxial cervical spine (C3 - T1);~* ages 18-80~Exclusion Criteria:~* Traumatic or tumor etiologies~* undergoing anterior-posterior operations~* neoplastic, or infectious conditions requiring surgery~* a history of previous anterior cervical spine surgery~* any patient requiring a halo vest~* patients on chronic steroids~* patients remaining intubated post-operatively (please see more under risks below)~* less than 18 years of age~* pregnant women~* no phone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Treatment 1; Dexamethasone (Type: EXPERIMENTAL): Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses.
- Treatment 0; Saline placebo (Type: PLACEBO_COMPARATOR): Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete